OncoMatch/Clinical Trials/NCT05431270
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
Is NCT05431270 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for non small cell lung cancer.
Treatment: Mavrostobart (PT199) · Tislelizumab · Gemcitabine + nab-Paclitaxel · Docetaxel · Pemetrexed · Gemcitabine · Carboplatin + Pemetrexed · Pembrolizumab + Carboplatin + Pemetrexed — This is a first-in-human, Phase 1/2, open-label, study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Mavrostobart (PT199) alone and in combination with a PD-1 inhibitor or chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Pancreatic Cancer
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Required: NT5E any tested (testing required; no eligibility threshold specified)
Disease stage
Required: Stage IV
at least one measurable lesion as defined by RECIST V1.1 criteria for solid tumors
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
adequate organ function confirmed at screening and within 72 hours of initiating treatment
Kidney function
adequate organ function confirmed at screening and within 72 hours of initiating treatment
Liver function
adequate organ function confirmed at screening and within 72 hours of initiating treatment
Adequate organ function confirmed at screening and within 72 hours of initiating treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Carolina BioOncology Institute · Huntersville, North Carolina
- Sarah Cannon Research Institute University of Oklahoma · Oklahoma City, Oklahoma
- SCRI Oncology Partners · Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center · Houston, Texas
- Tranquility Research · Webster, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify